HLS Therapeutics Inc.
HLTRF
$3.36
-$0.07-1.98%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 12.46% | -4.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.46% | -4.66% | |||
| Cost of Revenue | 12.29% | -1.60% | |||
| Gross Profit | 12.53% | -5.81% | |||
| SG&A Expenses | -6.24% | -0.54% | |||
| Depreciation & Amortization | -0.87% | 0.51% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.49% | -0.43% | |||
| Operating Income | 117.25% | -76.61% | |||
| Income Before Tax | 49.63% | -57.46% | |||
| Income Tax Expenses | -3,705.88% | -107.02% | |||
| Earnings from Continuing Operations | 65.93% | -42.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 65.93% | -42.94% | |||
| EBIT | 117.25% | -76.61% | |||
| EBITDA | 25.26% | -12.07% | |||
| EPS Basic | 67.95% | -44.11% | |||
| Normalized Basic EPS | 52.62% | -58.50% | |||
| EPS Diluted | 67.95% | -38.67% | |||
| Normalized Diluted EPS | 52.62% | -58.50% | |||
| Average Basic Shares Outstanding | 6.28% | -0.75% | |||
| Average Diluted Shares Outstanding | 6.28% | -0.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||